ROYALTY PHARMA PLC- CL A (RPRX) Stock Price, Quote, News and Overview
NASDAQ:RPRX - Nasdaq - GB00BMVP7Y09 - Common Stock - Currency: USD
RPRX Quote, Performance and Key Statistics
35.87
+0.6 (+1.7%)
The current stock price of RPRX is 35.87 USD. In the past month the price increased by 9.9%. In the past year, price increased by 36.03%.
RPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.36 | 734.92B | ||
| JNJ | JOHNSON & JOHNSON | 15.17 | 366.71B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.62 | 304.42B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.44 | 237.03B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.87 | 216.57B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
| PFE | PFIZER INC | 7.54 | 137.53B | ||
| SNY | SANOFI-ADR | 10.49 | 116.45B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.33B | ||
| GSK | GSK PLC-SPON ADR | 8.55 | 78.19B | ||
| ZTS | ZOETIS INC | 25.94 | 69.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.92 | 47.17B |
Related stock screener links
About RPRX
Company Profile
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.
Company Info
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022 US
CEO: Pablo Legorreta
Employees: 99
Phone: 12128830200
ROYALTY PHARMA PLC- CL A / RPRX FAQ
What is the stock price of ROYALTY PHARMA PLC- CL A today?
The current stock price of RPRX is 35.87 USD. The price increased by 1.7% in the last trading session.
What is the ticker symbol for ROYALTY PHARMA PLC- CL A stock?
The exchange symbol of ROYALTY PHARMA PLC- CL A is RPRX and it is listed on the Nasdaq exchange.
On which exchange is RPRX stock listed?
RPRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ROYALTY PHARMA PLC- CL A stock?
13 analysts have analysed RPRX and the average price target is 41.76 USD. This implies a price increase of 16.43% is expected in the next year compared to the current price of 35.87. Check the ROYALTY PHARMA PLC- CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ROYALTY PHARMA PLC- CL A worth?
ROYALTY PHARMA PLC- CL A (RPRX) has a market capitalization of 20.17B USD. This makes RPRX a Large Cap stock.
How many employees does ROYALTY PHARMA PLC- CL A have?
ROYALTY PHARMA PLC- CL A (RPRX) currently has 99 employees.
What are the support and resistance levels for ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a support level at 34.48. Check the full technical report for a detailed analysis of RPRX support and resistance levels.
Is ROYALTY PHARMA PLC- CL A (RPRX) expected to grow?
The Revenue of ROYALTY PHARMA PLC- CL A (RPRX) is expected to grow by 9.21% in the next year. Check the estimates tab for more information on the RPRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ROYALTY PHARMA PLC- CL A (RPRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RPRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RPRX, evaluating the profitability, health, valuation and growth aspects
- ROYALTY PHARMA PLC- CL A (RPRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ROYALTY PHARMA PLC- CL A (RPRX) Sales and EPS estimates to see what analysts future expectations are.
- ROYALTY PHARMA PLC- CL A (RPRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ROYALTY PHARMA PLC- CL A (RPRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart to make your own analysis
- ROYALTY PHARMA PLC- CL A (RPRX) Latest news and press-releases to stay up to date.
Does ROYALTY PHARMA PLC- CL A (RPRX) stock pay dividends?
ROYALTY PHARMA PLC- CL A (RPRX) has a dividend yield of 2.5%. The yearly dividend amount is currently 0.63. Check the full fundamental report for a detailed analysis of RPRX dividend history, reliability and sustainability.
When does ROYALTY PHARMA PLC- CL A (RPRX) report earnings?
ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of ROYALTY PHARMA PLC- CL A (RPRX)?
The PE ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.51. This is based on the reported non-GAAP earnings per share of 3.77 and the current share price of 35.87 USD. Check the full fundamental report for a full analysis of the valuation metrics for RPRX.
What is the Short Interest ratio of ROYALTY PHARMA PLC- CL A (RPRX) stock?
The outstanding short interest for ROYALTY PHARMA PLC- CL A (RPRX) is 7.59% of its float. Check the ownership tab for more information on the RPRX short interest.
RPRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 86.31% of all stocks.
RPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RPRX. While RPRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
RPRX Financial Highlights
Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 3.77. The EPS increased by 0.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 48.26% | ||
| ROA | 6.2% | ||
| ROE | 16.33% | ||
| Debt/Equity | 0.99 |
RPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RPRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.34% and a revenue growth 9.21% for RPRX